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Abstract: Europe is experiencing a third wave of COVID-19 due to the spread of highly transmissible
SARS-CoV-2 variants. A number of positive and negative factors constantly shape the rates of
COVID-19 infections, hospitalization, and mortality. Among these factors, the rise in increasingly
transmissible variants on one side and the effect of vaccinations on the other side create a picture
deeply different from that of the first pandemic wave. Starting from the observation that in several
European countries the number of COVID-19 infections in the second and third pandemic wave
increased without a proportional rise in disease severity and mortality, we hypothesize the existence
of an additional factor influencing SARS-CoV-2 dynamics. This factor consists of an immune defence
against severe COVID-19, provided by SARS-CoV-2-specific T cells progressively developing upon
natural exposure to low virus doses present in populated environments. As suggested by recent
studies, low-dose viral particles entering the respiratory and intestinal tracts may be able to induce
T cell memory in the absence of inflammation, potentially resulting in different degrees of immuniza-
tion. In this scenario, non-pharmaceutical interventions would play a double role, one in the short
term by reducing the detrimental spreading of SARS-CoV-2 particles, and one in the long term by
allowing the development of a widespread (although heterogeneous and uncontrollable) form of
immune protection.
Keywords: COVID-19; SARS-CoV-2; protective immunity; T cell responses; facial masking; fomites;
environmental exposure; memory T cells
1. Introduction
COVID-19 infection rates have resurged in most European countries after the 2020
summer period, giving rise to a tightly connected second and third wave of the pan-
demic. Despite the overall concern for the spread of the B.1.1.7 variant, which has been
reported to cause a more severe illness as compared to previous SARS-CoV-2 viruses [1–3],
COVID-19-associated mortality has not increased in parallel to the new surge of infections.
Additionally, some studies performed in Italy and Spain observed a lower pathogenicity of
COVID-19 in the second epidemic wave as compared to the first wave [4,5]. Several factors
may have contributed to the current relative decrease in COVID-19 infection to mortality
ratio as compared to the first wave. The optimization of clinical protocols for the manage-
ment of severe COVID-19 cases, together with the availability of new therapeutic tools,
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largely contributed to the decline of death rates. An additional factor potentially affecting
the decrease in COVID-19 fatalities is the younger mean age of affected subjects in the
second pandemic wave. However, an analysis of German data showed that the fatality rate
from COVID-19 has declined in all age groups, and that the older age groups drive the
overall reduction [6], indicating that the “young patient prevalence” cannot be considered
a universal explanation. A factor potentially confounding evaluations of epidemic trends
is the fact that the number of tests has increased by several orders of magnitude between
the first and the second/third pandemic wave, extending to unselected populations and
amplifying case detection. However, in European countries the constant increase in screen-
ing rates is not coupled to the trend of positive cases [7] indicating that the number of
positive cases does not depend only on testing efficiency. In this opinion, we explore the
hypothesis that low doses of SARS-CoV-2 present in populated environments may induce
virus-specific T cell responses, leading to progressive protective immunity. The hypothesis
that low virus doses leaking from facial masks may reduce the severity of disease among
people who become subsequently infected with SARS-CoV-2 was previously proposed in
order to explain the observed increase in asymptomatic infections in settings with universal
facial masking [8–10]. We extend this hypothesis by considering repeated contacts with
viral particles suspended in the air, or present on inanimate objects as a potential source of
T cell immunity and discuss this concept in the light of the latest immunological findings
showing the presence of SARS-CoV-2 immunity in non-infected subjects.
2. Uncoupled Trends of COVID-19 Infection and Mortality Rates in European
Countries, with a Focus on Italy’s Evolution of Disease Severity
According to the European Center for Disease Prevention and Control (ECDC) up-
dated surveillance reports, in 2021, the majority of European countries experienced high
rates of COVID-19 infection without a proportional increase in mortality rates [7]. Coun-
tries in the Europe geographical area at the time of manuscript submission could be roughly
divided into two groups, one with increasing COVID-19 cases and decreasing/constant
deaths (Georgia, Lithuania, Latvia, and Denmark), and one with both decreasing rates of
infections and decreasing deaths (the remaining 51 countries). Italy belongs to the second
group, with COVID-19 infection rates in decrease but still 3–4 times higher as compared to
the first outbreak of March–April 2020 [7]. An up-to-date analysis, reporting the distribu-
tion of COVID-19 severity in Italy from February 2020 to April 2021, clearly shows a neat
increase in the percentage of paucisymptomatic and asymptomatic cases, starting from
the end of the first epidemic cycle (Figure 1) [11]. A detailed look at the trends of disease
severity and mortality indicates that during the first COVID-19 wave, there was a clear
shared trend as for the number of intensive care unit (ICU) accessions and the number of
deaths [12]. Starting from October 2020, the dynamics of these indexes was decoupled from
the cumulative number of deaths no longer following the number of ICU accessions. Con-
sistent with previously shown dynamics of the relation between intensive care accessions
and fatalities [12], the coupled increase of different severity classes ends at the beginning
of summer 2020. From that time onward, the paucisymptomatic and asymptomatic cases
neatly outnumber the more severe cases. The convergence of two completely independent
analyses focusing on different endpoints is a signature of the robustness of the studied
phenomenon. It is worth noting that the analysis shown in Figure 1 deals with surely
ascertained cases, eliminating possible biases due to different definitions of ‘cause of death’.
Moreover, the use of percentages instead of absolute numbers does eliminate the biases
coming from the number of tests. The paucisymptomatic trend is probably the most infor-
mative, being less affected than the asymptomatic one to the presence of false positives to
RT-PCR testing strategy. Overall, we propose that the current epidemiological situation in
Italy (which mirrors Europe’s global situation, as reported by the ECDC) reflects on one
side the spread of more transmissible SARS-CoV-2 variants (responsible for the increase in
infections), and on the other side the progressive development of natural immunity among
the population (resulting in a large prevalence of asymptomatic and paucisymptomatic
cases). As discussed in the following sections, the severe lockdown measures imposed by
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several European countries during the first pandemic wave likely resulted in decreased
amounts of circulating virus, possibly influencing subsequent trends of disease severity.
The current epidemiological picture in European countries is in contrast with that of several
Latin American countries (i.e., Brazil, Mexico, Peru, Paraguay), where recurrent waves of
COVID-19 were coupled to a parallel increase in mortality rates [7]. Although multiple
and complex factors contribute to influence pandemic parameters, it may be inferred that
at least some countries that did not apply effective public health measures during the
first COVID-19 wave may have experienced more severe disease manifestations thereafter.
Finally, several considerations suggest that in the long-term, SARS-CoV-2 will lose its
potency and become endemic, similarly to common cold coronaviruses (CCCoVs) [13,14].
This process depends on multiple factors, including the duration of protective immunity,
susceptibility to reinfection, seasonality, competition with other circulating respiratory
viruses and control measures, as analyzed in detail elsewhere [13]. In this view, it may be
hypothesized that the variable degrees of immunity, possibly elicited by low-dose SARS-
CoV-2 particles present in the environment, may favor a softer transition of SARS-CoV-2 to
an endemic state, by contributing to a progressive decrease of COVID-19 severity.
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Figur 1. Epidemiological d ta of the Italia National Institute of Health (Istituto Superiore di Sanità,
Rome, Italy) showing th clinical status of COVID-19 patients from January 2020 to April 2021.
Colored bars represent the percentage of cases, respectively, with critical clinical conditions (top bars,
dark red, clinical manifestations affecting the respiratory tract and/or other organ systems that
require hospitalization in intensive care), with severe disease (orange bars, clinical manifestations
affecting the respirat ry tract and/or other organ systems that require hospitalization, not in intensive
care), with mild disease (yello bars, clinical manif stations affecti g the respiratory tract and/or
other organ systems that would not normally require hospitalization), with paucisymptomatic
disease (blue bars, mild and general symptoms e.g., general malaise, fever, fatigue, etc.), and with
asymptomatic disease (green bars, no apparent signs or symptoms of disease). Raw data in the
xlsx format are publicly available at the Istituto Superiore di Sanità website www.epicentro.iss.it/
coronavirus/sars-cov-2-dashboard (accessed on 23 April 2021).
3. Possible Role of Low Virus Doses in Eliciting a Protective Immune Response
against SARS-CoV-2
The concept that low viral exposure can lead to milder disease manifestations fol-
lowed by immunization provided the roots for the birth of vaccination procedures and has
been investigated in multiple experimental settings, ranging from parasites to different
viruses [15–20]. The use of low antigen doses is gaining increasing attention also in vaccine
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development, as several studies pointed to a higher quality of T cell responses obtained
through low levels of antigenic stimulation [21]. The observation that low virus doses
result in milder disease manifestations has found confirmation in mouse-adapted models
of MERS and SARS [22,23], in a hamster model of SARS-CoV-2 infection [24] and recently
in ferrets infected with SARS-CoV-2 [25]. Low dose challenge models for SARS-CoV-2 have
not yet been systematically developed [26]. A major impediment to this approach is that
low dose inoculation may lead to only a portion of animals being infected, thus requiring
large numbers of animals to achieve statistical significance. Nevertheless, some studies
have explored low dose challenge with SARS-CoV-2, using nebulized virus, or co-housing
of infected and uninfected animals [27–30]. Interestingly, human challenge models of
SARS-CoV-2 infection have also been proposed [31–33]. A fieldwork in humans supporting
the statement that low SARS-CoV-2 doses induce less severe disease manifestations as
compared to high doses is provided by studies performed on front-line healthcare workers.
This category has been previously shown to be at high risk for COVID-19 infection [34].
Recent studies on 2884 exposed healthcare workers showed that insufficient access to per-
sonal protective equipment was associated with increased likeliness of COVID-19 infection,
increased disease severity and prolonged duration, supporting the hypothesis that SARS-
CoV-2 viral inoculum could be associated with disease severity [35]. Low doses of viral
particles leaking through surgical masks have been proposed to act as a sort of “variolation”
process, increasing the proportion of asymptomatic SARS-CoV-2 infections and leading
to natural immunity [9,10]. This hypothesis seems confirmed by several studies showing
decreased COVID-19 infections and disease severity upon mask wearing [35–37]. Here,
we would like to take into consideration two additional factors potentially contributing to
the development of natural immunity to SARS-CoV-2 in part of the population. The first
factor is represented by the presence of the virus on collective objects, such as money,
handrails in public transportation and elevators, cash machines, intercoms and doorknobs.
Previous studies on SARS-CoV-1 have reported the presence of coronavirus on fomites
(inanimate objects) [38]. Moreover, contamination of environmental surfaces has been
proposed to explain unusual clusters of infection by SARS-CoV-1 [39,40]. The presence of
SARS-CoV-2 on fomites has been reported to occur both in hospitals and in non-hospital
settings [41–43]. The environmental contamination with SARS-CoV-2 has been previously
proposed to be scarcely relevant for the spread of infection throughout the population [44].
Recently, increased understanding of SARS-CoV-2 presence and stability on fomites led the
Centers for Disease Control and Prevention (CDC) to state that the relative risk of fomite
transmission of SARS-CoV-2 is low, compared with direct contact, droplet transmission,
or airborne transmission, as stated by a continuously updated report on this topic [45].
In fact, systematic analyses of virus stability on fomites indicated that the infectious titer
of SARS-CoV-2 on plastic or steel was greatly reduced after 72 h [46]. Moreover, sev-
eral studies that analyzed the infectivity of swabbed samples concluded that the virus
present on surfaces was not able to infect Vero E6 cells, presumably due to the low dose
of viral inoculum and to the decrease of virus viability [38,47]. This said, we postulate
that low doses of environmental SARS-CoV-2 may still be important in eliciting protective
immunity against COVID-19, due to the recurrent and multiple nature of antigenic contacts.
In addition to viral particles that enter the lungs through breathing, low doses of the virus
may also reach the gastrointestinal system through the enteral route, i.e., by touching buc-
cal mucosa or food with contaminated hands. In fact, hand washing (which is obviously
not a sterilization procedure) does not totally eliminate viral particles, as SARS-CoV-2
is not completely inactivated by normal detergents [46]. In this case the uptake of small
virus amounts may occur in the gut, where epithelial cells express ACE2 and can be effi-
ciently infected by SARS-CoV-2 [48]. SARS-CoV-2 exposure in the gastrointestinal tract
has been previously shown to be less pathogenic as compared to the respiratory tract [49]
and has been proposed to contribute to COVID-19 asymptomatic infections [32]. A factor
that may crucially influence the generation of protective immunity upon low antigenic
stimulation may be represented by the repeated contacts of the immune system with the
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pathogen, according to the principle of recall widely exploited in vaccination schedules.
Recurrent antigenic stimulation may also include contacts with a mixture of infectious and
non-infectious viral particles. In fact, although infectious SARS-CoV-2 particles present
on environmental surfaces decrease with time, viral antigens exposed on non-infectious
viruses may still be useful to alert the immune system. According to this principle, exposure
to inactivated pathogens is exploited by several vaccines, such as those against hepatitis A,
rabies, flu, and polio. Inactivated pathogens are known to be less effective than live germs
in eliciting protective immunity, and therefore vaccines with inactivated pathogens often
require several doses over time in order to develop efficient immunization. Interestingly,
whole microorganism vaccines (bacille Calmette–Guérin/BCG, oral polio vaccine, measles)
are known to induce a long-term boosting of innate immune responses termed trained
immunity, which is able to induce heterologous protection against other infections through
the reprogramming of innate immune cells. Trained immunity by whole microorganism
vaccines has been proposed to reduce SARS-CoV-2 susceptibility and severity [50,51]. Sev-
eral trials are underway to determine whether vaccination with BCG can help prevent
Covid-19 and will help to clarify this issue. Due to the very low (although detectable) doses
of SARS-CoV-2 present in the environment, a repeated contact with viral antigens may be
essential for the development of specific immune responses. In addition to the multiplicity
of antigenic contacts, immunization by low virus doses is likely influenced by a number
of other factors. Among these factors, the most important is likely the fitness of the host
immune systems, which will respond to antigenic challenges according to the individual’s
health, age, and immunological competence. Moreover, previous exposure to CCCoVs
is emerging as an important factor, potentially influencing the immune response against
SARS-CoV-2. In fact, several studies have identified T cells reactive against SARS-CoV-2
antigens in a relevant percentage (20-50%) of unexposed donors, i.e., pre-pandemic blood
samples [52–56]. Lymphocytes from pre-pandemic samples that react against SARS-CoV-2
antigens likely represent memory T cells generated upon previous exposure to endemic
CCCoVs, such as HCoV-OC43, HCoV-HKU1, HCoV-NL63 and HCoV-229 [57]. At present,
it is under debate whether such cross-reactive T cells are actually effective in providing
protection against COVID-19. Some studies indicate that a recent documented CCCoVs
infection is associated with less severe COVID-19, suggesting the involvement of lung-
localized memory T cells and B cells in protecting from severe disease manifestations [58].
By contrast, other studies have not detected an association between previous CCCoVs
infection and COVID-19 severity [59], or even reported a worse clinical outcome in COVID-
19 patients with CCCoV humoral immunity [60]. Interestingly, memory CD4+ and CD8+
T cells, cross-reactive against SARS-CoV-2 detected in unexposed healthy donors, failed to
expand in vitro, which suggests they have limited potential to function as part of a protec-
tive immune response against COVID-19 [61]. In addition to pre-existing T cell immunity,
recent studies showed that approximately 20% of pre-pandemic healthy donors possessed
SARS-CoV-2 cross-reactive serum antibodies, but these antibodies were not associated with
protection from SARS-CoV-2 infections, or disease severity [62].
4. Do Repeated Exposures to Low SARS-CoV-2 Doses induce T Cell Immunity?
A Possible Explanation for SARS-CoV-2-Specific T Cell Responses in
Non-Infected Subjects
Recent studies on immunological responses against SARS-CoV-2 provided a de-
tailed picture of immune signatures in COVID-19 patients (either with severe disease,
mildly symptomatic or asymptomatic) as compared to convalescent individuals, people
that have been in close contact with a COVID-19 patient, and unexposed healthy donors.
Such studies consistently reported a major role of T cell responses in developing im-
munity against SARS-CoV-2 [53,55,63–69]. Notably, T cell responses were shown to be
polyfunctional (involving both CD4+ and CD8+ lymphocytes), stable, and lasting for at
least six months after infection, even though anti-SARS-CoV-2 antibodies decline with
time [63,65,69]. Moreover, SARS-CoV-2-specific T cells with a stem-like memory phe-
notype (CCR7+CD127+CD45RA−/+TCF1+) were identified in COVID-19 convalescent
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subjects, even in the absence of detectable circulating antibodies, highlighting the role of
memory T cells in sustaining long-term immunity against SARS-CoV-2 [67]. A key study
that quantified SARS-CoV-2-specific memory T cell responses across distinct cohorts of
Swedish subjects confirmed the presence of pre-existing immunity against SARS-CoV-2 in
unexposed donors, but also highlighted unprecedented details in this regard. Specifically,
the authors found T cell responses directed against SARS-CoV-2 spike and/or membrane
proteins in 28% of healthy individuals who donated blood before the pandemic, in 46% of
healthy individuals who donated blood during the pandemic, in 67% of exposed family
members (who shared a household with a COVID-19 patient at the time of illness), in 87%
of convalescent subjects with a history of mild COVID-19, and in 100% of convalescent
individuals recovering from severe COVID-19 [67]. While the presence of T cells reactive
against SARS-CoV-2 in the blood of pre-pandemic donors is explained by previous in-
fection with CCCoVs, the nearly doubled percentage of SARS-CoV-2-reactive T cells in
subjects who donated blood after the beginning of the pandemic strongly suggests that
contact with viral particles present in the environment has elicited specific T cell responses.
Moreover, the striking increase of SARS-CoV-2-reactive T cells in exposed family members
(one third of whom were antibody-seronegative) further supports the hypothesis that a
low-dose viral inoculum, presumably reiterated over time, resulted in the development
of specific T cell responses. This hypothesis gains further support from recent studies
showing that individuals who stayed in close contact with a COVID-19-positive subject
developed T cell memory in the absence of infection [61]. Close contacts are often negative
to both nucleic acid testing and antibodies, indicating that SARS-CoV-2 failed to establish a
successful infection [61]. A similar observation was reported during the MERS epidemic,
where high-risk individuals (camel workers) who were nucleic acid testing negative and
antibody negative developed significant levels of MERS-CoV specific memory T cells [70].
It remains to be determined whether T cell responses generated in the absence of infection
can protect against subsequent challenges with SARS-CoV-2. However, previous studies on
influenza-specific T cells demonstrated that pre-existing memory CD4+ and CD8+ lympho-
cytes were able to provide protection against subsequent infections [71–73]. Also in the case
of coronaviruses, specific memory T cells have been shown to provide protective immunity
against severe infection [74–76], thus providing support to the hypothesis that SARS-CoV-
2-specific T cells developed upon natural exposure may prevent recurrent episodes of
severe COVID-19. In summary, the presence of T cells and antibodies against SARS-CoV-2
epitopes derived from previous CCCoVs infection has been consistently detected in un-
exposed individuals, although the role of such pre-existing immunity in protecting from
COVID-19 is not clear. Pre-existing immunity derived from CCCoVs cross-reactivity does
not exclude the possibility that SARS-CoV-2-specific T cells may develop upon contact with
sub-infectious virus doses. The latter immune response, although less efficient as compared
to that developed by COVID-19-infected individuals, is likely more specific as compared to
anti-CCCoVs cross-reactive immunity and may play a role in modulating the susceptibility
and severity of SARS-CoV-2 infection. Finally, an important question to consider is the
recent emergence of SARS-CoV-2 variants and whether pre-existing immune responses to
provide at least partial protection against mutated viral particles. While awaiting specific
studies to address this topic, the observation that immune responses develop against mul-
tiple different regions of viral proteins suggests that previous contacts with SARS-CoV-2
may favor population immunity against reinfection [14]. In this scenario, limiting SARS-
CoV-2 circulation through non-pharmaceutical interventions and the scale-up of vaccines
will restrain viral replication and consequently limit the generation of new variants until
population immunity is achieved.
5. Possible Differences in the Immune Response against High and Low
SARS-CoV-2 Doses
An explanation of the hypothesis that repeated antigenic stimulation with low SARS-
CoV-2 doses can elicit protective immunity may lay in the difference between the im-
mune mechanisms activated upon the encounter with high versus low doses of the virus
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(Figure 2). High doses of SARS-CoV-2 reaching the pulmonary alveoli are more likely to
result in enhanced kinetics of viral replication. Large amounts of viral particles can then
induce the death of airway epithelial cells with consequent release of damage-associated
molecular patterns (DAMPs). DAMPs trigger the production of inflammatory cytokines
and chemokines that recruit monocytes, neutrophils, and T cells to the lungs. An important
role in dictating the outcome of immune response to SARS-CoV-2 is played by mononuclear
phagocytes (MNP) present in the bronchoalveolar microenvironment. In fact, single cell
RNA-sequencing of bronchoalveolar fluid from patients with severe or mild COVID-19
showed that in severe cases, the MNP population was characterized by a depletion of
tissue-resident alveolar macrophages (FABP4+) and by an abundance of inflammatory
monocyte-derived macrophages (FCN1+SPP1+) [77]. Inflammatory macrophages are
responsible for chemotaxis, for propagating inflammation and for the generation of an
immune-suppressive milieu in SARS-CoV-2-infected tissues [78]. In the severe phase of
COVID-19, lung inflammation leads to diffuse alveolar damage and acute respiratory
distress syndrome, possibly accompanied by systemic inflammation, widespread coag-
ulopathy and multiorgan dysfunction. In this scenario, the immune system undergoes
profound alterations, including a dysregulated activation of monocytes and neutrophils and
a decrease in natural killer cells and peripheral blood T cells [78]. By contrast, low doses
of SARS-CoV-2 reaching the pulmonary alveoli are less likely to trigger massive viral
replication, unless the host T cell immunity is compromised. In the absence of inflamma-
tion, low doses of viral antigens come in contact with airway epithelial cells and alveolar
macrophages, therefore being processed and presented, respectively, to CD4+ T cells
through major histocompatibility complex (MHC) class II or to CD8+ T cells through MHC
class I. This process may result in the development of an adaptive immune response of
variable strength against SARS-CoV-2. In this regard, it is improbable that exposure to
low SARS-CoV-2 doses would result in sterilizing immunity, but the presence of memory
T cells in the lungs would minimize COVID-19 disease severity to that of a “common cold”
or asymptomatic disease. In fact, SARS-CoV-2–specific CD4+ T cells and CD8+ T cells
are associated with less COVID-19 disease severity during an ongoing SARS-CoV-2 infec-
tion [65,79]. Interestingly, CD4+ T cell response against SARS-CoV-2, which was found
in individuals exposed to the virus but not infected, has been proposed to occur also in
the absence of viral replication [61]. In fact, while a robust CD8+ response occurs in the
presence of abundant viral antigens usually generated by viral replication, CD4+ response
and subsequent immunological memory does not rely on endogenous viral replication,
but involves endocytosis/phagocytosis of exogenous viral antigens, which are mostly
derived from non-replicative viral particles or soluble viral proteins [61,80]. Therefore,
the formation of CD4+ T cell memory may be more easily achieved in uninfected exposed
individuals [61]. Reiterated exposures to sub-infectious virus doses may consolidate T cell
responses giving rise to memory T cells responsible for efficient long-term immunization.
Most likely, the generation of protective immunity upon exposure to low virus doses occurs
in individuals able to mount a proficient immune response, as low amounts of antigen
may fail to activate immune systems with suboptimal or compromised efficiency. The lack
of protective immunization by previous exposure to low virus doses may contribute to
explain why individuals with older age or concomitant pathologies experience more severe
forms of COVID-19 [81]. In particular, older adults have been reported to have a decline in
immune functions, a higher prevalence of chronic diseases and increased background levels
of inflammation. These factors, along with the inability to develop an efficient immuno-
logical memory upon natural exposure to environmental SARS-CoV-2, could collectively
account for more severe manifestations of COVID-19 in the older age group [82].
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not support a beneficial effect of SARS-CoV-2 exposure. In fact, the potential development 
Figure 2. Modifications occurring in the lung microenvironment upon exposure to high doses (left)
or low doses (right) of SARS-CoV-2. High (left) or low (right) numbers of SARS-CoV-2 particles
enter pulmonary alveoli and infect airway epithelial cells. In the left panel, massively infected
airway epithelial cells undergo cell death releasing damage-associated molecular patterns (DAMPs).
DAMPs activate neighboring cel s to produce inflammatory cytokines and recruit activated mono-
cytes, macrophages, and neutrophils. In the infla d lung microenvironm nt T lymphocytes,
after an initial activation, undergo functional exhaustion, while inflammatory monocyte-derived
macrophages (inflammatory MACs) substitute alveolar macrophages. In the right panel, low virus
doses come in contact with airway epithelial cells and alveolar macrophages. Viral particles are
processed and presented to T cells by lung epithelial cells and alveolar macrophages (alveolar MACs),
thus generating a controlled immune response. Protective immunity may evolve into efficient
long-term immunological memory upon repeated antigenic stimulation.
6. Conclusions
This opinion explores the hypothesis that naturally occurring exposures to low SARS-
CoV-2 doses may promote the development of immunological me ory, possibly contribut-
ing to protect against subsequent severe COVID-19 manifestations. This hypothesis is
tightly linked to the temporary dampening of virus spreading imposed by national lock-
downs. This effect may have allowed a higher number of low-dose exposures possibly
resulting in various degrees of immunization of non-infected subjects, who would mount a
more effective immune response upon a subsequent encounter with the virus. It is impor-
tant to stress that, even in case this hypothesis is confirmed by further studies, it does not
support a beneficial effect of SARS-CoV-2 exposure. In fact, the potential development of
protective immunity upon exposure to low dose viral particles would depend on multiple
and uncontrollable factors, such as the effective virus dose, the fitness of the host’s immune
system, the presence of comorbidities/inflammatory states, and the influence of individual
genetic factors (including several risk-associated genomic regions). Moreover, the spread
of new SARS-CoV-2 variants in vulnerable populations could still lead to greater disease
severity and mortality, supporting the continued implementation of protective measures
and the rapid vaccination of at-risk individuals. Finally, if repeated low-dose exposures to
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SARS-CoV-2 are actually able to elicit T cell-mediated immunological memory, they would
be useful in maintaining long-term anti-SARS-CoV-2 immunity post-vaccination. In fact,
prolonged SARS-CoV-2 antigen persistence (although at low doses) might represent a
continuous trigger for T cell responses, possibly expanding the antigenic repertoire to new
circulating COVID-19 variants. In this view, non-pharmaceutical interventions, vaccina-
tions, post-infection immunity, and possibly protection conferred by low environmental
SARS-CoV-2, may altogether contribute to maintain post-pandemic immunity.
Author Contributions: A.Z., M.L.D.A. and F.F. wrote the manuscript. R.R. provided essential
contribution in editing the manuscript. A.G. took care of biostatistics. R.D.M. provided essential
expertise. All authors have read and agreed to the published version of the manuscript.
Funding: This work was supported by an Italian Association for Cancer Research (AIRC) Investigator
Grant to A.Z. (AIRC IG 2017 Ref: 20744).
Institutional Review Board Statement: The observational epidemiological studies reported in
Figure 1 were performed by the Istituto Superiore di Sanità as institutionally delegated to the
integrated health surveillance of the SARS-CoV-2 pandemic, pursuant to the Ordinance of Head of
the Civil Protection Department, n. 640 of 27 February 2020 and in compliance with the provisions
of the circulars of the Ministry of Health n. 5889 of 25 February 2020 and no. 7922 of 9 March 2020.
Further information can be found at the ISS website www.epicentro.iss.it/coronavirus/sars-cov-2-
dashboard (accessed on 23 April 2021); www.epicentro.iss.it/coronavirus/pdf/informazioni-privacy-
iss-sorveglianza-integrata-covid-19.pdf (accessed on 23 April 2021).
Data Availability Statement: Raw data reported in Figure 1 are publicly available in the xlsx format
at the Istituto Superiore di Sanità website www.epicentro.iss.it/coronavirus/sars-cov-2-dashboard
(accessed on 23 April 2021).
Acknowledgments: We are grateful to Antonino Bella, Patrizio Pezzotti and all the COVID-19
supervisory group at the Istituto Superiore di Sanità for providing epidemiological data shown in
Figure 1.
Conflicts of Interest: The authors declare that the research was conducted in the absence of any
commercial or financial relationships that could represent a potential conflict of interest.
References
1. Challen, R.; Brooks-Pollock, E.; Read, J.M.; Dyson, L.; Tsaneva-Atanasova, K.; Danon, L. Risk of mortality in patients infected
with SARS-CoV-2 variant of concern 202012/1: Matched cohort study. BMJ 2021, 372, n579. [CrossRef] [PubMed]
2. Davies, N.G.; Jarvis, C.I.; Group, C.C.-W.; Edmunds, W.J.; Jewell, N.P.; Diaz-Ordaz, K.; Keogh, R.H. Increased mortality in
community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature 2021, 593, 270–274. [CrossRef]
3. Grint, D.J.; Wing, K.; Williamson, E.; McDonald, H.I.; Bhaskaran, K.; Evans, D.; Evans, S.J.; Walker, A.J.; Hickman, G.;
Nightingale, E.; et al. Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England, 16 November to 5 Febru-
ary. Euro. Surveill. 2021, 26, 2100256. [CrossRef] [PubMed]
4. Borghesi, A.; Golemi, S.; Carapella, N.; Zigliani, A.; Farina, D.; Maroldi, R. Lombardy, Northern Italy: COVID-19 second wave
less severe and deadly than the first? A preliminary investigation. Infect. Dis. (Lond.) 2021, 53, 1–6.
5. Soriano, V.; Ganado-Pinilla, P.; Sanchez-Santos, M.; Gomez-Gallego, F.; Barreiro, P.; de Mendoza, C.; Corral, O. Main differences
between the first and second waves of COVID-19 in Madrid, Spain. Int. J. Infect. Dis. 2021, 105, 374–376. [CrossRef]
6. Oke, J.; Howdon, D.; Heneghan, C. Declining COVID-19 Case Fatality Rates across All Ages: Analysis of German Data.
Available online: www.cebm.net/covid-19/declining-covid-19-case-fatality-rates-across-all-ages-analysis-of-german-data/
(accessed on 21 May 2021).
7. European Center for Disease Prevention and Control (ECDC). Covid-19 Country Overviews. Available online: https://covid19-
country-overviews.ecdc.europa.eu/#2_Global (accessed on 14 May 2021).
8. Gandhi, M.; Beyrer, C.; Goosby, E. Masks Do More Than Protect Others During COVID-19: Reducing the Inoculum of SARS-CoV-2
to Protect the Wearer. J. Gen. Intern. Med. 2020, 35, 3063–3066. [CrossRef]
9. Gandhi, M.; Rutherford, G.W. Facial Masking for Covid-19—Potential for “Variolation” as We Await a Vaccine. N. Engl. J. Med.
2020, 383, e101. [CrossRef]
10. Spinelli, M.A.; Glidden, D.V.; Gennatas, E.D.; Bielecki, M.; Beyrer, C.; Rutherford, G.; Chambers, H.; Goosby, E.; Gandhi, M.
Importance of non-pharmaceutical interventions in lowering the viral inoculum to reduce susceptibility to infection by SARS-
CoV-2 and potentially disease severity. Lancet Infect. Dis. 2021, in press. [CrossRef]
11. Istituto Superiore di Sanità (National Institute of Health), COVID-19—Monitoraggio del Rischio. Rome, Italy, 2021. Available online:
www.iss.it/grafici-settimanali (accessed on 23 April 2021).
Viruses 2021, 13, 961 10 of 12
12. Bizzarri, M.; Di Traglia, M.; Giuliani, A.; Vestri, A.; Fedeli, V.; Prestininzi, A. New statistical RI index allow to better track the
dynamics of COVID-19 outbreak in Italy. Sci. Rep. 2020, 10, 22365. [CrossRef]
13. Shaman, J.; Galanti, M. Will SARS-CoV-2 become endemic? Science 2020, 370, 527–529. [CrossRef]
14. Veldhoen, M.; Simas, J.P. Endemic SARS-CoV-2 will maintain post-pandemic immunity. Nat. Rev. Immunol. 2021, 21, 131–132. [CrossRef]
15. Bretscher, P.A.; Wei, G.; Menon, J.N.; Bielefeldt-Ohmann, H. Establishment of stable, cell-mediated immunity that makes
“susceptible” mice resistant to Leishmania major. Science 1992, 257, 539–542. [CrossRef] [PubMed]
16. Buchmeier, M.J.; Welsh, R.M.; Dutko, F.J.; Oldstone, M.B. The virology and immunobiology of lymphocytic choriomeningitis
virus infection. Adv. Immunol. 1980, 30, 275–331. [PubMed]
17. Hessell, A.J.; Poignard, P.; Hunter, M.; Hangartner, L.; Tehrani, D.M.; Bleeker, W.K.; Parren, P.W.; Marx, P.A.; Burton, D.R.
Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 2009, 15,
951–954. [CrossRef] [PubMed]
18. Rasmussen, R.A.; Sharma, P.L.; Hu, Y.; Ruprecht, R.M. Vaccine protection by subinfectious doses of a live murine leukemia virus.
Leukemia 1999, 13, S94–S95. [CrossRef]
19. Strong, R.; La Rocca, S.A.; Paton, D.; Bensaude, E.; Sandvik, T.; Davis, L.; Turner, J.; Drew, T.; Raue, R.; Vangeel, I. Viral dose
and immunosuppression modulate the progression of acute BVDV-1 infection in calves: Evidence of long term persistence after
intra-nasal infection. PLoS ONE 2015, 10, e0124689. [CrossRef]
20. Zinkernagel, R.M.; Hengartner, H. T-cell-mediated immunopathology versus direct cytolysis by virus: Implications for HIV and
AIDS. Immunol. Today 1994, 15, 262–268. [CrossRef]
21. Billeskov, R.; Beikzadeh, B.; Berzofsky, J.A. The effect of antigen dose on T cell-targeting vaccine outcome. Hum. Vaccin. Immunother.
2019, 15, 407–411. [CrossRef]
22. Li, K.; Wohlford-Lenane, C.L.; Channappanavar, R.; Park, J.E.; Earnest, J.T.; Bair, T.B.; Bates, A.M.; Brogden, K.A.; Flaherty, H.A.;
Gallagher, T.; et al. Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice. Proc. Natl. Acad.
Sci. USA 2017, 114, E3119–E3128. [CrossRef] [PubMed]
23. Roberts, A.; Deming, D.; Paddock, C.D.; Cheng, A.; Yount, B.; Vogel, L.; Herman, B.D.; Sheahan, T.; Heise, M.; Genrich, G.L.; et al.
A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog. 2007, 3, e5. [CrossRef]
24. Imai, M.; Iwatsuki-Horimoto, K.; Hatta, M.; Loeber, S.; Halfmann, P.J.; Nakajima, N.; Watanabe, T.; Ujie, M.; Takahashi, K.;
Ito, M.; et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc. Natl.
Acad. Sci. USA 2020, 117, 16587–16595. [CrossRef] [PubMed]
25. Ryan, K.A.; Bewley, K.R.; Fotheringham, S.A.; Slack, G.S.; Brown, P.; Hall, Y.; Wand, N.I.; Marriott, A.C.; Cavell, B.E.;
Tree, J.A.; et al. Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective im-
munity. Nat. Commun. 2021, 12, 81. [CrossRef] [PubMed]
26. Khoury, D.S.; Wheatley, A.K.; Ramuta, M.D.; Reynaldi, A.; Cromer, D.; Subbarao, K.; O’Connor, D.H.; Kent, S.J.; Davenport, M.P.
Measuring immunity to SARS-CoV-2 infection: Comparing assays and animal models. Nat. Rev. Immunol. 2020, 20, 727–738.
[CrossRef] [PubMed]
27. Chan, J.F.; Yuan, S.; Zhang, A.J.; Poon, V.K.; Chan, C.C.; Lee, A.C.; Fan, Z.; Li, C.; Liang, R.; Cao, J.; et al. Surgical Mask Partition
Reduces the Risk of Noncontact Transmission in a Golden Syrian Hamster Model for Coronavirus Disease 2019 (COVID-19).
Clin. Infect. Dis. 2020, 71, 2139–2149. [CrossRef] [PubMed]
28. Chan, J.F.; Zhang, A.J.; Yuan, S.; Poon, V.K.; Chan, C.C.; Lee, A.C.; Chan, W.M.; Fan, Z.; Tsoi, H.W.; Wen, L.; et al. Simulation of
the Clinical and Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian Hamster Model:
Implications for Disease Pathogenesis and Transmissibility. Clin. Infect. Dis. 2020, 71, 2428–2446. [CrossRef]
29. Kim, Y.I.; Kim, S.G.; Kim, S.M.; Kim, E.H.; Park, S.J.; Yu, K.M.; Chang, J.H.; Kim, E.J.; Lee, S.; Casel, M.A.B.; et al. Infection and
Rapid Transmission of SARS-CoV-2 in Ferrets. Cell Host Microbe 2020, 27, 704–709.e2. [CrossRef]
30. Sia, S.F.; Yan, L.M.; Chin, A.W.H.; Fung, K.; Choy, K.T.; Wong, A.Y.L.; Kaewpreedee, P.; Perera, R.; Poon, L.L.M.;
Nicholls, J.M.; et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature 2020, 583, 834–838. [CrossRef]
31. Deming, M.E.; Michael, N.L.; Robb, M.; Cohen, M.S.; Neuzil, K.M. Accelerating Development of SARS-CoV-2 Vaccines—The Role
for Controlled Human Infection Models. N. Engl. J. Med. 2020, 383, e63. [CrossRef]
32. Hausdorff, W.P.; Flores, J. Low-dose and oral exposure to SARS-CoV-2 may help us understand and prevent severe COVID-19.
Int. J. Infect. Dis. 2021, 103, 37–41. [CrossRef]
33. Nguyen, L.C.; Bakerlee, C.W.; McKelvey, T.G.; Rose, S.M.; Norman, A.J.; Joseph, N.; Manheim, D.; McLaren, M.R.; Jiang, S.;
Barnes, C.F.; et al. Evaluating Use Cases for Human Challenge Trials in Accelerating SARS-CoV-2 Vaccine Development. Clin.
Infect. Dis. 2021, 72, 710–715. [CrossRef]
34. Nguyen, L.H.; Drew, D.A.; Graham, M.S.; Joshi, A.D.; Guo, C.G.; Ma, W.; Mehta, R.S.; Warner, E.T.; Sikavi, D.R.; Lo, C.H.; et al.
Risk of COVID-19 among front-line health-care workers and the general community: A prospective cohort study. Lancet Public
Health 2020, 5, e475–e483. [CrossRef]
35. Kim, H.; Hegde, S.; LaFiura, C.; Raghavan, M.; Sun, N.; Cheng, S.; Rebholz, C.M.; Seidelmann, S.B. Access to personal protective
equipment in exposed healthcare workers and COVID-19 illness, severity, symptoms and duration: A population-based case-
control study in six countries. BMJ Glob. Health 2021, 6, e004611. [CrossRef] [PubMed]
36. Epperly, D.E.; Rinehart, K.R.; Caney, D.N. COVID-19 Aerosolized Viral Loads, Environment, Ventilation, Masks, Exposure Time,
Severity, And Immune Response: A Pragmatic Guide Of Estimates. medRxiv 2021. [CrossRef]
Viruses 2021, 13, 961 11 of 12
37. Hendrix, M.J.; Walde, C.; Findley, K.; Trotman, R. Absence of Apparent Transmission of SARS-CoV-2 from Two Stylists after
Exposure at a Hair Salon with a Universal Face Covering Policy—Springfield, Missouri, May 2020. MMWR Morb. Mortal. Wkly.
Rep. 2020, 69, 930–932. [CrossRef]
38. Dowell, S.F.; Simmerman, J.M.; Erdman, D.D.; Wu, J.S.; Chaovavanich, A.; Javadi, M.; Yang, J.Y.; Anderson, L.J.; Tong, S.; Ho, M.S.
Severe acute respiratory syndrome coronavirus on hospital surfaces. Clin. Infect. Dis. 2004, 39, 652–657. [CrossRef]
39. Lee, S.H. The SARS epidemic in Hong Kong. J. Epidemiol. Community Health 2003, 57, 652–654. [CrossRef]
40. Olsen, S.J.; Chang, H.L.; Cheung, T.Y.; Tang, A.F.; Fisk, T.L.; Ooi, S.P.; Kuo, H.W.; Jiang, D.D.; Chen, K.T.; Lando, J.; et al.
Transmission of the severe acute respiratory syndrome on aircraft. N. Engl. J. Med. 2003, 349, 2416–2422. [CrossRef]
41. Chia, P.Y.; Coleman, K.K.; Tan, Y.K.; Ong, S.W.X.; Gum, M.; Lau, S.K.; Lim, X.F.; Lim, A.S.; Sutjipto, S.; Lee, P.H.; et al. Detection of
air and surface contamination by SARS-CoV-2 in hospital rooms of infected patients. Nat. Commun. 2020, 11, 2800. [CrossRef]
42. Mouchtouri, V.A.; Koureas, M.; Kyritsi, M.; Vontas, A.; Kourentis, L.; Sapounas, S.; Rigakos, G.; Petinaki, E.; Tsiodras, S.;
Hadjichristodoulou, C. Environmental contamination of SARS-CoV-2 on surfaces, air-conditioner and ventilation systems. Int. J.
Hyg. Environ. Health 2020, 230, 113599. [CrossRef] [PubMed]
43. Santarpia, J.L.; Rivera, D.N.; Herrera, V.; Morwitzer, M.J.; Creager, H.; Santarpia, G.W.; Crown, K.K.; Brett-Major, D.; Schnaubelt, E.;
Broadhurst, M.J.J.M. Aerosol and surface transmission potential of SARS-CoV-2. Sci. Rep. 2020, 10, 12732. [CrossRef]
44. Goldman, E. Exaggerated risk of transmission of COVID-19 by fomites. Lancet Infect. Dis. 2020, 20, 892–893. [CrossRef]
45. European Center for Disease Prevention and Control (ECDC). Science Brief: SARS-CoV-2 and Surface (Fomite) Transmission for
Indoor Community Environments. 2021. Available online: www.cdc.gov/coronavirus/2019-ncov/more/science-and-research/
surface-transmission.html#print (accessed on 14 May 2021).
46. Van Doremalen, N.; Bushmaker, T.; Morris, D.H.; Holbrook, M.G.; Gamble, A.; Williamson, B.N.; Tamin, A.; Harcourt, J.L.;
Thornburg, N.J.; Gerber, S.I.; et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N. Engl. J. Med.
2020, 382, 1564–1567. [CrossRef] [PubMed]
47. Mondelli, M.U.; Colaneri, M.; Seminari, E.M.; Baldanti, F.; Bruno, R. Low risk of SARS-CoV-2 transmission by fomites in real-life
conditions. Lancet Infect. Dis. 2020, 21, e112. [CrossRef]
48. Lamers, M.M.; Beumer, J.; van der Vaart, J.; Knoops, K.; Puschhof, J.; Breugem, T.I.; Ravelli, R.B.; van Schayck, J.P.; Mykytyn, A.Z.;
Duimel, H.Q.J.S. SARS-CoV-2 productively infects human gut enterocytes. Science 2020, 369, 50–54. [CrossRef] [PubMed]
49. Lee, A.C.; Zhang, A.J.; Chan, J.F.; Li, C.; Fan, Z.; Liu, F.; Chen, Y.; Liang, R.; Sridhar, S.; Cai, J.P.; et al. Oral SARS-CoV-2 Inoculation
Establishes Subclinical Respiratory Infection with Virus Shedding in Golden Syrian Hamsters. Cell Rep. Med. 2020, 1, 100121.
[CrossRef] [PubMed]
50. Mantovani, A.; Netea, M.G. Trained Innate Immunity, Epigenetics, and Covid-19. N. Engl. J. Med. 2020, 383, 1078–1080. [CrossRef] [PubMed]
51. Netea, M.G.; Giamarellos-Bourboulis, E.J.; Dominguez-Andres, J.; Curtis, N.; van Crevel, R.; van de Veerdonk, F.L.;
Bonten, M. Trained Immunity: A Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection. Cell 2020, 181,
969–977. [CrossRef]
52. Bacher, P.; Rosati, E.; Esser, D.; Martini, G.R.; Saggau, C.; Schiminsky, E.; Dargvainiene, J.; Schröder, I.; Wieters, I.;
Khodamoradi, Y.J.I. Low-avidity CD4+ T cell responses to SARS-CoV-2 in unexposed individuals and humans with severe
COVID-19. Immunity 2020, 53, 1258–1271.e5. [CrossRef] [PubMed]
53. Braun, J.; Loyal, L.; Frentsch, M.; Wendisch, D.; Georg, P.; Kurth, F.; Hippenstiel, S.; Dingeldey, M.; Kruse, B.; Fauchere, F.J.N.
SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature 2020, 587, 270–274. [CrossRef]
54. Grifoni, A.; Weiskopf, D.; Ramirez, S.I.; Mateus, J.; Dan, J.M.; Moderbacher, C.R.; Rawlings, S.A.; Sutherland, A.; Premkumar, L.;
Jadi, R.S.J.C. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals.
Cell 2020, 181, 489–1501.e15. [CrossRef]
55. Le Bert, N.; Tan, A.T.; Kunasegaran, K.; Tham, C.Y.L.; Hafezi, M.; Chia, A.; Chng, M.H.Y.; Lin, M.; Tan, N.; Linster, M.; et al.
SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature 2020, 584, 457–462. [CrossRef]
56. Mateus, J.; Grifoni, A.; Tarke, A.; Sidney, J.; Ramirez, S.I.; Dan, J.M.; Burger, Z.C.; Rawlings, S.A.; Smith, D.M.; Phillips, E.; et al.
Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science 2020, 370, 89–94. [CrossRef]
57. Sette, A.; Crotty, S. Pre-existing immunity to SARS-CoV-2: The knowns and unknowns. Nat. Rev. Immunol. 2020, 20, 457–458.
[CrossRef] [PubMed]
58. Sagar, M.; Reifler, K.; Rossi, M.; Miller, N.S.; Sinha, P.; White, L.F.; Mizgerd, J.P. Recent endemic coronavirus infection is associated
with less-severe COVID-19. J. Clin. Investig. 2021, 131, e143380. [CrossRef]
59. Ringlander, J.; Martner, A.; Nilsson, S.; Westin, J.; Lindh, M.; Hellstrand, K. Verified infections with endemic common cold
coronaviruses do not entail significant protection against SARS-CoV-2. J. Infect. Dis. 2021. [CrossRef]
60. Focosi, D.; Genoni, A.; Lucenteforte, E.; Tillati, S.; Tamborini, A.; Spezia, P.G.; Azzi, L.; Baj, A.; Maggi, F. Previous Humoral
Immunity to the Endemic Seasonal Alphacoronaviruses NL63 and 229E Is Associated with Worse Clinical Outcome in COVID-19
and Suggests Original Antigenic Sin. Life 2021, 11, 298. [CrossRef] [PubMed]
61. Wang, Z.; Yang, X.; Zhong, J.; Zhou, Y.; Tang, Z.; Zhou, H.; He, J.; Mei, X.; Tang, Y.; Lin, B.; et al. Exposure to SARS-CoV-2
generates T-cell memory in the absence of a detectable viral infection. Nat. Commun. 2021, 12, 1724. [CrossRef]
62. Anderson, E.M.; Goodwin, E.C.; Verma, A.; Arevalo, C.P.; Bolton, M.J.; Weirick, M.E.; Gouma, S.; McAllister, C.M.;
Christensen, S.R.; Weaver, J.; et al. Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not
associated with protection. Cell 2021, 184, 1858–1864.e10. [CrossRef] [PubMed]
Viruses 2021, 13, 961 12 of 12
63. Bilich, T.; Nelde, A.; Heitmann, J.S.; Maringer, Y.; Roerden, M.; Bauer, J.; Rieth, J.; Wacker, M.; Peter, A.; Horber, S.; et al. T cell and
antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals.
Sci. Transl. Med. 2021, 13. [CrossRef]
64. Bonifacius, A.; Tischer-Zimmermann, S.; Dragon, A.C.; Gussarow, D.; Vogel, A.; Krettek, U.; Godecke, N.; Yilmaz, M.;
Kraft, A.R.M.; Hoeper, M.M.; et al. COVID-19 immune signatures reveal stable antiviral T cell function despite declining
humoral responses. Immunity 2021, 54, 340–354.e6. [CrossRef]
65. Dan, J.M.; Mateus, J.; Kato, Y.; Hastie, K.M.; Yu, E.D.; Faliti, C.E.; Grifoni, A.; Ramirez, S.I.; Haupt, S.; Frazier, A.; et al.
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 2021, 371. [CrossRef] [PubMed]
66. Ni, L.; Ye, F.; Cheng, M.-L.; Feng, Y.; Deng, Y.-Q.; Zhao, H.; Wei, P.; Ge, J.; Gou, M.; Li, X.J.I. Detection of SARS-CoV-2-specific
humoral and cellular immunity in COVID-19 convalescent individuals. Immunity 2020, 52, 971–977.e3. [CrossRef]
67. Sekine, T.; Perez-Potti, A.; Rivera-Ballesteros, O.; Stralin, K.; Gorin, J.B.; Olsson, A.; Llewellyn-Lacey, S.; Kamal, H.; Bogdanovic, G.;
Muschiol, S.; et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell 2020, 183,
158–168.e14. [CrossRef] [PubMed]
68. Snyder, T.M.; Gittelman, R.M.; Klinger, M.; May, D.H.; Osborne, E.J.; Taniguchi, R.; Zahid, H.J.; Kaplan, I.M.; Dines, J.N.;
Noakes, M.T.; et al. Magnitude and dynamics of the T-cell response to SARS-CoV-2 infection at both individual and population
levels. MedRxiv 2020. [CrossRef]
69. Zuo, J.; Dowell, A.C.; Pearce, H.; Verma, K.; Long, H.M.; Begum, J.; Aiano, F.; Amin-Chowdhury, Z.; Hallis, B.; Stapley, L.; et al.
Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. Nat. Immunol. 2021, 22,
620–626. [CrossRef] [PubMed]
70. Zhao, J.; Alshukairi, A.N.; Baharoon, S.A.; Ahmed, W.A.; Bokhari, A.A.; Nehdi, A.M.; Layqah, L.A.; Alghamdi, M.G.;
Al Gethamy, M.M.; Dada, A.M.; et al. Recovery from the Middle East respiratory syndrome is associated with antibody and
T-cell responses. Sci. Immunol. 2017, 2, eaan5393. [CrossRef] [PubMed]
71. McKinstry, K.K.; Strutt, T.M.; Kuang, Y.; Brown, D.M.; Sell, S.; Dutton, R.W.; Swain, S.L. Memory CD4+ T cells protect against
influenza through multiple synergizing mechanisms. J. Clin. Investig. 2012, 122, 2847–2856. [CrossRef]
72. Sridhar, S.; Begom, S.; Bermingham, A.; Hoschler, K.; Adamson, W.; Carman, W.; Bean, T.; Barclay, W.; Deeks, J.J.; Lalvani, A.
Cellular immune correlates of protection against symptomatic pandemic influenza. Nat. Med. 2013, 19, 1305–1312. [CrossRef]
73. Wilkinson, T.M.; Li, C.K.; Chui, C.S.; Huang, A.K.; Perkins, M.; Liebner, J.C.; Lambkin-Williams, R.; Gilbert, A.; Oxford, J.;
Nicholas, B.; et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in
humans. Nat. Med. 2012, 18, 274–280. [CrossRef]
74. Channappanavar, R.; Fett, C.; Zhao, J.; Meyerholz, D.K.; Perlman, S. Virus-specific memory CD8 T cells provide substantial
protection from lethal severe acute respiratory syndrome coronavirus infection. J. Virol. 2014, 88, 11034–11044. [CrossRef]
75. Li, C.K.; Wu, H.; Yan, H.; Ma, S.; Wang, L.; Zhang, M.; Tang, X.; Temperton, N.J.; Weiss, R.A.; Brenchley, J.M.; et al. T cell responses
to whole SARS coronavirus in humans. J. Immunol. 2008, 181, 5490–5500. [CrossRef] [PubMed]
76. Zhao, J.; Zhao, J.; Mangalam, A.K.; Channappanavar, R.; Fett, C.; Meyerholz, D.K.; Agnihothram, S.; Baric, R.S.; David, C.S.;
Perlman, S. Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses. Immunity
2016, 44, 1379–1391. [CrossRef]
77. Liao, M.; Liu, Y.; Yuan, J.; Wen, Y.; Xu, G.; Zhao, J.; Cheng, L.; Li, J.; Wang, X.; Wang, F.J.; et al. Single-cell landscape of
bronchoalveolar immune cells in patients with COVID-19. Nat. Med. 2020, 26, 842–844. [CrossRef] [PubMed]
78. Vabret, N.; Britton, G.J.; Gruber, C.; Hegde, S.; Kim, J.; Kuksin, M.; Levantovsky, R.; Malle, L.; Moreira, A.; Park, M.D.J.I.
Immunology of COVID-19: Current state of the science. Immunity 2020, 52, 910–941. [CrossRef]
79. Rydyznski Moderbacher, C.; Ramirez, S.I.; Dan, J.M.; Grifoni, A.; Hastie, K.M.; Weiskopf, D.; Belanger, S.; Abbott, R.K.; Kim, C.;
Choi, J.; et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease
Severity. Cell 2020, 183, 996–1012.e19. [CrossRef] [PubMed]
80. Blum, J.S.; Wearsch, P.A.; Cresswell, P. Pathways of antigen processing. Annu. Rev. Immunol. 2013, 31, 443–473. [CrossRef] [PubMed]
81. O’Driscoll, M.; Ribeiro Dos Santos, G.; Wang, L.; Cummings, D.A.T.; Azman, A.S.; Paireau, J.; Fontanet, A.; Cauchemez, S.;
Salje, H. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature 2021, 590, 140–145. [CrossRef] [PubMed]
82. British Society for Immunology, The Ageing Immune System and COVID-19. 2020. Available online: www.immunology.org/
sites/default/files/BSI_Ageing_COVID-19_Report_Nov2020_FINAL.pdf (accessed on 14 May 2021).
